Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

(2013) Takashi Seto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

(2012) J. E. Karp et al.   CLINICAL CANCER RESEARCH

The  2Na+/K+-ATPase is critical for skeletal and heart muscle function in zebrafish

(2012) C. Doganli et al.   JOURNAL OF CELL SCIENCE

“The Octet”: Eight Protein Kinases that Control Mammalian DNA Replication

(2012) Melvin L. DePamphilis et al.   Frontiers in Physiology

CaMKII in the Cardiovascular System: Sensing Redox States

(2011) Jeffrey R. Erickson et al.   PHYSIOLOGICAL REVIEWS

Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2Checkpoint and Inhibition of Homologous Recombinational DNA Repair

(2010) Meredith A. Morgan et al.   CANCER RESEARCH

In vitro and In vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762

(2010) J. B. Mitchell et al.   CLINICAL CANCER RESEARCH

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

(2008) S. D. Zabludoff et al.   MOLECULAR CANCER THERAPEUTICS